- Market Capitalization, $K 110,510
- Shares Outstanding, K 44,204
- Annual Sales, $ 0 K
- Annual Income, $ -53,980 K
- 60-Month Beta 1.08
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 1.05
|Period||Period Low||Period High||Performance|
| || |
-0.04 (-1.57%)since 10/25/22
| || |
+0.28 (+12.61%)since 08/25/22
| || |
-2.52 (-50.20%)since 11/24/21
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...
Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...
US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...
Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG;...
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory...
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe...
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show...
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?